Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Sionna Therapeutics, Inc. is focused on developing novel medicines to treat cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [1][3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company aiming to revolutionize CF treatment through innovative medicines that stabilize CFTR's nucleotide binding domain 1 (NBD1) [3] - The company is advancing a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation, which affects NBD1 [3] - Sionna is also developing complementary CFTR modulators to work synergistically with its NBD1 stabilizers to enhance CFTR function [3] Investor Relations - Sionna plans to use its Investor Relations website for disclosing material nonpublic information and complying with Regulation FD [4] - Investors are encouraged to monitor the Investor Relations website along with press releases, SEC filings, public conference calls, presentations, and webcasts for updates [4]